Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01867294 · ClinicalTrials.gov registry record · Phase 2
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
A Phase 2 study, sponsored by Academic and Community Cancer Research United.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01867294 is a Phase 2 study that has completed, run by Academic and Community Cancer Research United. The registered enrollment target is 19 participants.
The verdict
NCT01867294, a Phase 2 study, has completed, sponsored by Academic and Community Cancer Research United.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.
Interventions
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Spironolactone
- DRUG Doxycycline
- PROCEDURE Management of Therapy Complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2012-08-31 |
| Est. Completion | 2014-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01867294
The ClinicalTrials.gov registry entry for NCT01867294 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Academic and Community Cancer Research United, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01867294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01867294 about?
NCT01867294 is a clinical study titled "Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab". This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin ...
What is the current status of trial NCT01867294?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2012-08-31. Estimated completion is 2014-06-13.
What interventions are being tested in trial NCT01867294?
The interventions under investigation include: Placebo (OTHER), Questionnaire Administration (OTHER), Spironolactone (DRUG), Doxycycline (DRUG), Management of Therapy Complications (PROCEDURE).
Who is sponsoring clinical trial NCT01867294?
This trial is sponsored by Academic and Community Cancer Research United, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.